ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
Andrey E. Karateev
Abstract
Open-access reader
Andrey E. Karateev
Abstract
Open-access reader
The paper provides the clinical characteristics of etoricoxib (Arcoxia), a new selective cyclooxygenase-2 inhibitor having unique properties, which permits it to be distinguished among other nonsteroidal anti-inflammatory agents.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The paper provides the clinical characteristics of etoricoxib (Arcoxia), a new selective cyclooxygenase-2 inhibitor having unique properties, which permits it to be distinguished among other nonsteroidal anti-inflammatory agents.
Key concepts: Etoricoxib, Cyclooxygenase, Nonsteroidal, Pharmacology, Chemistry, Medicine, Biochemistry, Enzyme